首页   按分类浏览 期刊浏览 卷期浏览 Overview of Recent Clinical Pharmacokinetic Studies with Acitretin (Ro 10-1670, Etretin)
Overview of Recent Clinical Pharmacokinetic Studies with Acitretin (Ro 10-1670, Etretin)

 

作者: C.J. Brindley,  

 

期刊: Dermatology  (Karger Available online 1989)
卷期: Volume 178, issue 2  

页码: 79-87

 

ISSN:1018-8665

 

年代: 1989

 

DOI:10.1159/000248397

 

出版商: S. Karger AG

 

关键词: Acitretin;Ro 10-1670;Etretin;Etretinate;Ro 10-9359;Clinical pharmacokinetics;Metabolism

 

数据来源: Karger

 

摘要:

Following oral administration of acitretin with food, peak plasma concentrations of unchanged drug (Ro 10-1670) are reached within 4 h. The mean absolute bioavailabihty of acitretin is 59% with high interpatient variability consistent with that of etretinate. Taking acitretin with food results in an increased and more consistent bioavailabihty. The drug appears to be extensively distributed throughout the body without unexpected accumulation and the elimination half-life is approximately 50 h. Acitretin has a profound pharmacokinetic advantage over etretinate because it is eliminated more rapidly from the body; etretinate is sequestered into fatty tissue due to its greater lipophilicity creating a deep compartment from which it is only slowly released. Acitretin is eliminated entirely by the metabolism and the resultant metabolites are excreted via the kidney and bile.

 

点击下载:  PDF (1844KB)



返 回